Cypherpunk Technologies Inc Dossier - Source-backed chat

Cypherpunk Technologies Inc

CYPHNASDAQ

SectorFinancials

IndustryAsset Management & Custody Banks

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.92Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $314.7M

Enterprise Value $308M

Shares Outstanding 106.5M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) presents a unique dual-exposure investment vehicle. The company has transitioned its core strategy to a digital asset treasury model anchored by Zcash (ZEC), aiming to accumulate up to 5% of the total circulating supply. This strategy mirrors MicroStrategy's Bitcoin accumulation model but focuses on privacy-preserving technology. Backed by Winklevoss Capital, Cypherpunk offers public equity investors direct, liquid exposure to the privacy coin sector. This core crypto strategy is complemented by a legacy biopharmaceutical business through its subsidiary, Leap Therapeutics, which is developing sirexatamab (FDA Fast Track designated in May 2026 for metastatic colorectal cancer). Despite recent volatility from a Zcash protocol vulnerability disclosure in June 2026, the long-term thesis remains intact due to institutional backing, regulatory clarity following the SEC's closure of its Zcash Foundation investigation in early 2026, and the growing demand for privacy-enhancing technologies in an AI-driven world.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$0.90

Mean target$0.90

High · most bullish analyst$0.90

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

Tightening global regulations, such as the EU's upcoming 2027 ban on anonymous wallets, severely restrict Zcash liquidity and depress token prices. Additional technical vulnerabilities or protocol exploits in Zcash's shielded pools permanently damage investor confidence, leaving Cypherpunk's treasury position deeply underwater. High cash burn from legacy biotech operations forces dilutive equity raises under the company's ATM program.

Base CaseCentral scenario

$1.5855%

Cypherpunk steadily executes its treasury strategy, increasing its ZEC holdings toward the 5% network target. Zcash prices stabilize and recover from the June 2026 vulnerability sell-off, supported by the SEC's decision not to pursue enforcement action against the Zcash Foundation. Leap Therapeutics continues clinical development of sirexatamab with moderate progress, maintaining compliance with Nasdaq listing requirements.

Bull CaseUpside scenario

$3.0025%

Zcash experiences massive institutional adoption as the premier privacy-preserving digital store of value, driven by rising global capital controls and AI-driven financial surveillance. The ZEC price surges toward historical highs, significantly boosting Cypherpunk's net asset value (NAV). Concurrently, Leap Therapeutics secures a lucrative global licensing deal or positive Phase 3 data for sirexatamab in DKK1-high colorectal cancer, validating the biotech pipeline and providing non-dilutive funding.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Direct Public Equity Exposure to Privacy Infrastructure: Offers a regulated, Nasdaq-listed vehicle for investors to gain exposure to Zcash without the complexities of direct custody.
Strong Institutional Backing: Anchored by a $50 million private placement led by Winklevoss Capital, with strategic advisors including Zcash founder Zooko Wilcox and ECC CEO Josh Swihart.
Favorable Regulatory Shift: The SEC formally closed its investigation into the Zcash Foundation in early 2026 with no enforcement action, removing a major overhang for institutional capital.
Biotech Optionality: The subsidiary Leap Therapeutics provides high-upside optionality with sirexatamab, which holds FDA Fast Track designation and has demonstrated strong clinical efficacy in DKK1-high colorectal cancer patients.

Key Investment Risks

Extreme Asset Concentration: The company's balance sheet and stock price are highly correlated with the volatile price of Zcash (ZEC).
Regulatory and Compliance Headwinds: Privacy-focused digital assets face ongoing scrutiny from global regulators, including potential transaction bans in key jurisdictions like the European Union.
Technical and Protocol Risks: Vulnerabilities in zero-knowledge cryptographic implementations (such as the Orchard shielded pool counterfeiting flaw disclosed in June 2026) can cause severe price drops.
Capital Dilution: Continued biotech development and treasury accumulation may require utilizing the company's $200 million at-the-market (ATM) equity program, diluting existing shareholders.

Thesis Invalidation Triggers

A permanent regulatory ban on Zcash trading or custody by major US financial regulators.
Failure of the Zcash developer community to successfully implement formal verification or resolve critical protocol vulnerabilities.
Termination or complete failure of Leap Therapeutics' clinical programs for sirexatamab, eliminating the biotech valuation floor.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.